Navigation Links
NW BIO TO PRESENT AT WORLD VACCINE CONGRESS 2015
Date:4/9/2015

BETHESDA, Md., April 9, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Leslie J. Goldman, Senior Vice President Business Development, will present at the World Vaccine Congress 2015 that is being held in Washington, DC from April 7- 9.

Mr. Goldman will be speaking as part of the co-located Cancer & Immunotherapy conference.  The Company's presentation will take place on Thursday, April 9, at 10:25 a.m. EDT on Level 2, Room 207B at the Walter E. Washington Convention Center.  There will be a live audio webcast of the 20 minute presentation available at http://nwbio.com/webcasts/ 

During his presentation, Mr. Goldman will provide an overview of the Company's vaccine technology, product pipeline and clinical programs.

The World Vaccine Congress comprises seven co-located conferences where scientists, biotech specialists, pharma representatives and business leaders discuss critical scientific advances.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression.  It has completed enrollment in the Phase I portion of the trial.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - http://photos.prnewswire.com/prnh/20110329/SF73084LOGO

 


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
2. Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015
3. Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting
4. ANI Pharmaceuticals Presents At 14th Annual Needham Healthcare Conference
5. Cambrex To Present At The 14th Annual Needham Healthcare Conference
6. Asterias Biotherapeutics to Present at Needham Healthcare Conference
7. MEI Pharma to Present at Needham Healthcare Conference
8. Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica
9. Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
10. Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
11. Data Highlighting Delcaths Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2020)... Vt. (PRWEB) , ... January 10, 2020 , ... By mid-January, many people’s New Year’s ... offering a “New Year, New Life” Eight Night Wellness Retreat for the 2020 season. , ... 2020 dates to include an extra week in May and the first weekend of October. ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... Institute of Silicon Valley, has this week announced the latest medical breakthrough for ... Molybdenum-Rhenium rod in a patient. , The newly FDA cleared MiRus Europa™ Pedicle ...
(Date:1/7/2020)... ... January 07, 2020 , ... Ironsphere, a ... providers, announced today it has been selected by MetLife Stadium for Privileged Access ... “As part of our ongoing commitment to maintain the highest of security policies, ...
Breaking Medicine Technology:
(Date:1/23/2020)... AVON, Colo. (PRWEB) , ... January 23, 2020 , ... ... (SCA), announced it will kick off its first-ever Save More Lives Challenge on Feb. ... engaging the public in lifesaving techniques that can decrease the number one cause of ...
(Date:1/22/2020)... LARGO, Fla. (PRWEB) , ... January 22, 2020 , ... ... will provide free dental services for low-income, underinsured individuals at its Largo, FL ... exams and x-rays , fillings , cleanings and ...
(Date:1/12/2020)... ... 2020 , ... Cecelia Health ( http://www.ceceliahealth.com ), a leading ... for over a decade to transform lives and health outcomes for patients and ... By optimizing the mix of expert clinician and digital touchpoints in clinically tested ...
(Date:1/10/2020)... ... ... WellHaven Pet Health, a family of companion animal veterinary hospitals headquartered in ... 2020, LEAD WELL with WOMEN. The community will be showcased at the VMX 2020 ... with WOMEN is to empower women, engage all, connect, and help you lead your ...
(Date:1/10/2020)... ... 10, 2020 , ... NW Women’s Fitness , a ... for all women. In search for a valuable nutrition solution, NW Women’s Fitness ... , For nearly 30 years, Balanced Habits, headquartered in Southern California, has helped ...
Breaking Medicine News(10 mins):